Centre Hospitalier de Cholet

Az itteni vizsgálatok

Miről szól a helyszín 52 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák11 vizsgálat
• Áttétes emlőrák6 vizsgálat
• Gyomor- és nyelőcsőrák5 vizsgálat
• Vastagbélrák5 vizsgálat
• Asztma4 vizsgálat
• Petefészekrák4 vizsgálat
• Szívelégtelenség4 vizsgálat
• Polymyalgia rheumatica3 vizsgálat
• Arthritis psoriatica1 vizsgálat
• Colitis ulcerosa1 vizsgálat
• Deep vein thrombosis and pulmonary embolism1 vizsgálat
• Elhízás1 vizsgálat
• és még 11

Fázis

• 3. fázis27 vizsgálat
• 2. fázis20 vizsgálat
• 2/3. fázis1 vizsgálat
• 4. fázis1 vizsgálat

Állapot

• Toboroz23 vizsgálat
• Fut, nem toboroz13 vizsgálat
• Lezárult13 vizsgálat
• Még nem toboroz1 vizsgálat
• Felfüggesztve1 vizsgálat
• Leállították1 vizsgálat

Fő szponzor

• UNICANCER7 vizsgálat
• Intergroupe Francophone de Cancerologie Thoracique5 vizsgálat
• ARCAGY/ GINECO GROUP3 vizsgálat
• Federation Francophone de Cancerologie Digestive3 vizsgálat
• Unicancer3 vizsgálat
• és még 26

Futó vizsgálatok

• Még nem toboroz

  ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.

  NCT07737964· 3. fázis· University Hospital, Montpellier· Forrás

• Toboroz

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· 2. fázis· Eli Lilly and Company· Forrás

• Toboroz

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· 3. fázis· Novo Nordisk A/S· Forrás

• Toboroz

  A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma

  2025-522640-41-00· 2. fázis· Eli Lilly & Co.· Forrás

• Még nem toboroz

  Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

  NCT07150403· 2. fázis· Federation Francophone de Cancerologie Digestive· Forrás

• Toboroz

  Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)

  2024-518385-26-01· 3. fázis· Centre Hospitalier Regional Et Universitaire De Brest· Forrás

• Toboroz

  A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

  NCT07219173· 2. fázis· Eli Lilly and Company· Forrás

  Contact: Pauline BEURRIER (principal investigator)

• Toboroz

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

  NCT06680596· 2. fázis· UNICANCER· Forrás

• Toboroz

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· 3. fázis· Pfizer· Forrás

• Toboroz

  Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

  NCT06606730· 3. fázis· UNICANCER· Forrás

• Toboroz

  Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

  NCT06245356· 2. fázis· UNICANCER· Forrás

• Toboroz

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction

  2023-508798-94-00· 3. fázis· Assistance Publique Hopitaux De Paris· Forrás

• Toboroz

  A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.

  2023-509340-10-00· 3. fázis· OSE Immunotherapeutics· Forrás

• Fut, nem toboroz

  Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and immunotherapy ( Pembrolizumab)

  NCT04262687· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás

• Toboroz

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· 3. fázis· ARCAGY/ GINECO GROUP· Forrás

  Contact: Sylvère GUILLEMOIS

• Fut, nem toboroz

  Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

  NCT06331312· 3. fázis· Novartis Pharmaceuticals· Forrás

• Toboroz

  First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

  NCT06253611· 2. fázis· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás

  Contact: Thonas CENTRE HOSPITALIER DE CHOLET, MD

• Fut, nem toboroz

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás

• Fut, nem toboroz

  Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

  NCT05856695· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás

• Toboroz

  Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

  NCT05627375· 3. fázis· Centre Hospitalier Universitaire de Saint Etienne· Forrás

• Fut, nem toboroz

  Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

  NCT05476796· 2. fázis· UNICANCER· Forrás

• Fut, nem toboroz

  Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

  NCT05781308· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás

• Toboroz

  Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

  NCT05692999· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás

• Fut, nem toboroz

  Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence

  NCT05297617· 2. fázis· Unicancer· Forrás

• Toboroz

  Met Non Small Cell Cancer Registry (MOMENT)

  NCT05376891· EMD Serono Research & Development Institute, Inc.· Forrás

  Contact: Philippe Masson (principal investigator)

• Toboroz

  Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

  NCT05183984· 2. fázis· ARCAGY/ GINECO GROUP· Forrás

• Fut, nem toboroz

  Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

  NCT04884282· 2. fázis· Fondazione Ricerca Traslazionale· Forrás

• Fut, nem toboroz

  A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

  NCT05049798· Janssen Pharmaceutica N.V., Belgium· Forrás

• Fut, nem toboroz

  OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC

  NCT03806309· 2. fázis· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás

• Fut, nem toboroz

  Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

  NCT04621188· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás

• Fut, nem toboroz

  Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, high burden disease: chemotherapy and combination of hormonotherapy with abemaciclib.

  NCT04158362· 3. fázis· Unicancer· Forrás

• Toboroz

  A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab

  NCT04183608· 4. fázis· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Forrás

• Fut, nem toboroz

  Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

  NCT03977194· 3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás

• Lezárult

  IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting

  NCT02967289· 3. fázis· UNICANCER· Forrás

• Lezárult

  PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

  NCT03079011· 3. fázis· UNICANCER· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Szívelégtelenség4 toboroz
• Tüdőrák4 toboroz
• Gyomor- és nyelőcsőrák3 toboroz
• Asztma2 toboroz
• Petefészekrák2 toboroz
• Vastagbélrák2 toboroz
• Áttétes emlőrák1 toboroz
• Deep vein thrombosis and pulmonary embolism1 toboroz
• Elhízás1 toboroz
• Gyermekkori daganatok1 toboroz
• Hasnyálmirigyrák1 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)1 toboroz
• Méhtestrák1 toboroz
• Polymyalgia rheumatica1 toboroz
• Tripla negatív emlőrák1 toboroz

Lezárt vizsgálatok

• Lezárult

  A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

  NCT05813288· 3. fázis· Areteia Therapeutics Inc.· Forrás

• Lezárult

  Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.

  2022-502372-22-01· 2. fázis· Unicancer· Forrás

• Leállították

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· 2. fázis· UNICANCER· Forrás

• Lezárult

  Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

  NCT05767034· 3. fázis· Novartis Pharmaceuticals· Forrás

• Lezárult

  PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy-

  2022-501217-31-00· 2/3. fázis· Fondation Franc.Cancerologie Digestive· Forrás

• Lezárult

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· 3. fázis· Bayer AG· Forrás

• Lezárult

  Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy

  NCT05025826· Nantes University Hospital· Forrás

• Lezárult

  An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

  NCT05243680· 3. fázis· GlaxoSmithKline· Forrás

• Fut, nem toboroz

  VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.

  NCT03686306· 3. fázis· Rennes University Hospital· Forrás

• Fut, nem toboroz

  OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

  NCT04713514· 2. fázis· ARCAGY/ GINECO GROUP· Forrás

• Fut, nem toboroz

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· 3. fázis· Tesaro, Inc.· Forrás

• Lezárult

  Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

  NCT03469960· 3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás

• Lezárult

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· 3. fázis· Federation Francophone de Cancerologie Digestive· Forrás

• Lezárult

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· 3. fázis· Canadian Cancer Trials Group· Forrás